top of page
Browse by category
Search


Researcher 2 Researcher and Bariatric News - The Podcasts
Spend an engaging hour with Researcher 2 Researcher and Bariatric News as we explore a range of topics in Bariatric and Metabolic...


Journal Watch 23/4/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


GLP-1 therapies have potential to treat Bardet-Biedl syndrome
A Monell Chemical Senses Center study has identified that GLP-1 receptor agonists as a promising therapeutic for managing the metabolic...


Laparoscopic OAGB is an effective revisional option after failed open VGB
Laparoscopic one anastomosis gastric bypass (OAGB) is an effective revisional surgery after failed open vertical banded gastroplasty...


BMS delivers functional, CVD and musculoskeletal improvements in adolescents out to six years
Adolescents with severe obesity who underwent BMS were seen to have improved functional mobility, cardiovascular parameters and...


Lilly's oral GLP-1 orforglipron consistent with injectable GLP-1 medicines
The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in...


Glucose-lowering drugs may have protective effects against the development of Alzheimer’s disease
A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering drugs...


MetaVia reveals positive data for DA-1726 dual oxyntomodulin analog agonist
MetaVia has revealed positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a...


Nimacimab + tirzepatide combination results in 30% weight loss
Skye Bioscience's novel CB1 antibody, nimacimab in combination with the dual GLP-1/GIP agonist, tripeptide, resulted in greater than 30%...


Sharp rise in use of new GLPs as metformin, sulfonylureas and insulin declines
Investigators from Mass General Brigham who examined claims data from nearly two million people between 2021 and 2023, have reported a...
Browse by tag






bottom of page